NASDAQ: AFIBAcutus Medical Inc Stock
$0.93-0.07 (-7%)
Updated Mar 17, 2023
AFIB Price
$0.93
Fair Value Price
N/A
Market Cap
$26.35M
52 Week Low
$0.48
52 Week High
$2.17
P/E
-0.3x
P/B
0.46x
P/S
1.58x
PEG
N/A
Dividend Yield
N/A
Revenue
$15.76M
Earnings
-$85.99M
Gross Margin
-112.7%
Operating Margin
-512.5%
Profit Margin
-545.5%
Debt to Equity
0.98
Operating Cash Flow
-$95M
Beta
1.2
Next Earnings
May 10, 2023
Ex-Dividend
N/A
Next Dividend
N/A
AFIB Overview
Acutus Medical, Inc., an arrhythmia management company, designs, manufactures, and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. The company's product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact force ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Acutus Medical, Inc. was incorporated in 2011 and is headquartered in Carlsbad, California.
Zen Score
–
Industry Average (31)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AFIB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AFIB is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AFIB is good value based on its book value relative to its share price (0.46x), compared to the US Medical Devices industry average (3.75x)
P/B vs Industry Valuation
AFIB is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more AFIB due diligence checks available for Premium users.
Be the first to know about important AFIB news, forecast changes, insider trades & much more!
AFIB News
Valuation
AFIB fair value
Fair Value of AFIB stock based on Discounted Cash Flow (DCF)
Price
$0.93
Fair Value
$1.88
Undervalued by
50.46%
AFIB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AFIB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.3x
Industry
93.94x
Market
21.81x
AFIB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.46x
Industry
3.75x
AFIB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AFIB's financial health
Profit margin
Revenue
$3.6M
Net Income
-$20.4M
Profit Margin
-560.5%
AFIB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
AFIB's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$114.6M
Liabilities
$56.8M
Debt to equity
0.98
AFIB's short-term assets ($93.89M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AFIB's short-term assets ($93.89M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AFIB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$23.8M
Investing
$5.9M
Financing
-$458.0k
AFIB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AFIB vs Medical Device Stocks
Acutus Medical Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.